INCITE Attracts Another ‘Superstar,’ Adds Might to Precision Health

Posted: Updated:
Dr. Chandan Sen is the latest scientist recruited by the INCITE program. Dr. Chandan Sen is the latest scientist recruited by the INCITE program.

The Indiana University Precision Health Initiative (PHI), now at the two-year mark, recently announced progress toward its goal to unleash the power of personalized medicine to cure one cancer and one childhood disease over the next decade. One engine driving that machine is the human talent that has been recruited to the state, supported by a $25 million INCITE grant. The Lilly Endowment Inc. funds aim to link the scientists to the business sector and spur translational research. The number of these “superstar” scientists is growing, and leaders say the business benefits are certain to follow.

“INCITE allows the IU School of Medicine (IUSM) to bring talent to Indy that are desired also by the public sector—that’s the real purpose of INCITE,” says PHI Principal Investigator and IU Associate Vice President for Clinical Affairs Dr. Anantha Shekhar. “We’ve leveraged the PHI and INCITE programs—combined the two opportunities, so we can really go after superstars, as opposed to one source helping us recruit good talent, but not superstar talent.”

The INCITE program, announced one year ago, aims to hire 10 prominent scientists who are renowned in their field. Three have already joined the forces at IU. The latest was announced just this month: Dr. Chandan Sen will oversee IUSM’s Indiana Center for Regenerative Medicine and Engineering.

He joins INCITE scientists Dr. Michael Weiss, who is creating better insulins for patients with diabetes, and Dr. Roland Herzog, an immunologist developing a variety of innovative programs for children’s diseases. Shekhar says IUSM will announce a fourth scientist soon, who is a prominent expert in asthma and childhood diseases.

“That will transform our ability to do pediatric research at Riley [Hospital for Children at IU Health] and will be a close collaboration with Lilly,” says Shekhar. “He will be very much responsible for the [PHI] childhood disease pillar and hopefully will bring some new areas as well, in terms of closer partnership with Lilly and Riley.”

INCITE’s industry partners, including Indianapolis-based Cook Regentec and West Lafayette-based Cook Biotech, plus the Lilly backing, boost Indy’s recruitment package. Shekhar says the companies are “also co-recruiting [the researchers], in a sense, as their partner; I think that adds twice the value for our scientists who come here.”

“This is an autocatalytic process, where each recruitment facilitates the next, and we’re building a great set of teams here in Indy and throughout the state,” says Weiss, who also sees the value of working closely with industry. “The commercialization process is the only way to get from an academic lab or hospital to patients. And the resources required to go through Phase 1, 2, 3, clinical trials and, ultimately, FDA approval of a new drug, are not the forte of the academic world, but requires a commercialization partner.”

Shekhar says those academic and industry relationships will create economic and commercial ripple effects.

“Every one of these recruits is going to create one or two companies with multiple commercializable ideas. It’s going to, essentially, make us a powerhouse in innovation and commercialization,” says Shekhar. “That dimension will probably take about a decade to fully mature, but it’s going to be a long-lasting legacy beyond the medical research.”

Both Shekhar and Weiss point to 16 Tech as fertile soil for startups; the 60-acre innovation community in Indianapolis is in close proximity to IUSM and Riley. Weiss co-founded Thermalin Diabetes, Inc. in a Cleveland Clinic incubator and is “excited to explore if we can move part of the company to 16 Tech and have a branch and labs in Indy.”

“The prospect of having incubators located near IUSM in Indy is exciting. 16 Tech can do for Indy and its economic vitalization what the biotech spinoffs have done around Purdue—the whole cluster in the electronics/engineering space. Here in Indianapolis, we have the potential for exciting growth and job creation in biotech,” says Weiss. “It’s two birds with one stone; we enhance the academic strength of IU, and we also contribute to job creation in Indy. That’s a great vision that combines our academic leadership with our civic leadership.”

Weiss says Indiana is working to strengthen its ability to attract early-stage funding.
Weiss believes the PHI will add momentum to the discovery process, which will lead to the creation of startups and partnerships with major companies.
Shekhar says the heavy involvement of industry partners is creating value for Indianapolis.
  • Perspectives

    • Regional Investment Proposal Could be a Game Changer for Quality of Place Initiatives in Indiana

      While quality of place may be defined differently by people, a growing number of Hoosiers recognize the importance of this issue. In particular, the impact of quality of place on talent attraction and retention in a geographic area cannot be ignored. The future of every community is dependent on quality of place. Like many Midwestern states, Indiana is not growing at the same pace as areas in the southern and western regions of the United States.



Company Name:
Confirm Email:
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections


  • Most Popular Stories

    • The Vogue opened as a movie house in 1938, then reopened as a nightclub in 1977. (Picture Courtesy: The Vogue)

      Tech Vets Purchase Popular Indy Nightclub

      A group of Indianapolis tech entrepreneurs has bought a popular nightclub in the city's Broad Ripple neighborhood. High Alpha co-founder Eric Tobias and former MOBI executives Scott Kraege and Andrew Davis say they will retain the Vogue's current staff to manage the venue's day-to-day operations. The new owners say they will detail plans to reinvigorate the Vogue through enhanced fan experience and engagement in the coming months. Tobias, Kraege and Davis purchased the Vogue...

    • (Image courtesy of the Indianapolis Colts.)

      Colts Announce 2019 Regular Season Schedule

      The 2019 NFL schedule is out and the Indianapolis Colts will play in several high-profile games. All three of the Colts’ 2019 primetime games will be on the road against defending division champions. 

    • Bryan Brenner is the CEO of FirstPerson and a founding partner of Performance Lab.

      FirstPerson Execs Launch Performance Lab

      A new firm founded by executives from Indianapolis-based FirstPerson says it wants to help companies strengthen performance. Performance Lab uses a field test known as the Performance Climate Survey, which provides insights into a company’s performance culture. Founding Partner Bryan Brenner, who is also the CEO of FirstPerson, says the firm has already landed a number of early customers, including Goodwill Industries, the Indy Chamber and the Central Indiana Community Foundation.

    • Skilled Nursing Facility Proposed for Merrillville

      A new $7 million skilled nursing facility is being proposed in Merrillville. Our partners at The Times of Northwest Indiana report the development would include five residential buildings outfitted with 12 beds, a dining area, beauty salon and spa. 

    • 2019 'Stellar' Finalists Announced

      Lieutenant Governor Suzanne Crouch has unveiled the finalists for the 2019 Stellar Communities Program. The four regions selected will receive a planning grant and work with the Indiana Communities Institute at Ball State University on project alignment and continued planning efforts. Stellar Communities, launched in 2011, is led by the Indiana Office of Community and Rural Affairs and aims to boost community and economic development and promote local and regional partnerships.